JAK2 Gene Thrombocythemia Type 3 Somatic Genetic Test
At DNA Labs UAE, we offer the JAK2 Gene Thrombocythemia Type 3 Somatic Genetic Test. This test helps diagnose essential thrombocythemia and determine if the condition is caused by a somatic mutation in the JAK2 gene.
Test Details
The JAK2 gene is responsible for producing a protein called Janus kinase 2, which plays a crucial role in regulating the production and maturation of blood cells. Mutations in the JAK2 gene can lead to abnormal activation of the protein, resulting in various blood disorders.
Thrombocythemia type 3, also known as essential thrombocythemia, is a condition characterized by the overproduction of platelets in the blood. This can increase the risk of blood clots.
Test Components
- Test Name: JAK2 Gene Thrombocythemia Type 3 Somatic Genetic Test
- Price: 4400.0 AED
- Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
- Report Delivery: 3 to 4 Weeks
- Method: NGS Technology
- Test Type: Cancer
- Doctor: Oncologist
- Test Department: Genetics
Pre Test Information
Prior to undergoing the JAK2 Gene Thrombocythemia Type 3 Somatic Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session may be conducted to draw a pedigree chart of family members affected by the JAK2 Gene Thrombocythemia Type 3 Somatic Genetic Test gene.
Test Procedure
Somatic NGS genetic testing, also known as Next-Generation Sequencing testing, involves analyzing non-germline cells in the body for genetic mutations. In the case of the JAK2 Gene Thrombocythemia Type 3 Somatic Genetic Test, a sample of somatic cells, such as blood cells, will be analyzed for mutations in the JAK2 gene.
Treatment and Management
If a mutation is detected in the JAK2 gene, it can guide treatment decisions and help monitor the progression of essential thrombocythemia. Targeted therapies have been developed to specifically inhibit the activity of the mutated JAK2 protein, which can help manage symptoms and complications associated with the condition.
It is important to note that genetic testing should always be done under the guidance of a healthcare professional who can interpret the results and provide appropriate medical advice.
| Test Name | JAK2 Gene Thrombocythemia type 3 somatic Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for JAK2 Gene Thrombocythemia type 3, somatic NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with JAK2 Gene Thrombocythemia type 3, somatic NGS Genetic DNA Test gene JAK2 |
| Test Details |
The JAK2 gene is a gene that provides instructions for making a protein called Janus kinase 2. This protein plays a crucial role in signaling pathways that regulate the production and maturation of blood cells. Mutations in the JAK2 gene can lead to abnormal activation of the protein, resulting in various blood disorders. Thrombocythemia type 3, also known as essential thrombocythemia, is a condition characterized by the overproduction of platelets in the blood. Platelets are responsible for blood clotting, and an excessive number of platelets can lead to an increased risk of blood clots. Somatic NGS genetic testing refers to Next-Generation Sequencing testing of somatic cells, which are non-germline cells in the body. This type of testing can identify genetic mutations that occur in cells during a person’s lifetime, as opposed to being inherited from their parents. A somatic NGS genetic test for JAK2 gene thrombocythemia type 3 would involve analyzing a sample of an individual’s somatic cells, such as blood cells, for mutations in the JAK2 gene. This test can help diagnose essential thrombocythemia and determine if the condition is caused by a somatic mutation in the JAK2 gene. If a mutation is detected in the JAK2 gene, it can guide treatment decisions and help monitor the progression of the disease. Some targeted therapies have been developed to specifically inhibit the activity of the mutated JAK2 protein, which can help manage the symptoms and complications associated with essential thrombocythemia. It is important to note that genetic testing should always be done under the guidance of a healthcare professional who can interpret the results and provide appropriate medical advice. |
